Evidence map›Paper›PMID 37180166›Full record

ArticleFrontiers in immunology2023

Prediction of liver cancer prognosis based on immune cell marker genes.

Jianfei Liu, Junjie Qu, Lingling Xu, Chen Qiao, Guiwen Shao, Xin Liu, Hui He, Jian Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. [ERI3 expression is elevated in hepatocellular carcinoma and correlates with poor patient prognosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jianfei LiuDepartment of Interventional Therapy, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Junjie QuInterventional Medicine Center, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China.
Lingling XuDepartment of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Chen QiaoDepartment of Interventional Therapy, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Guiwen ShaoDepartment of Interventional Therapy, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Xin LiuDepartment of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Hui HeDepartment of Laparoscopic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Jian ZhangDepartment of Interventional Therapy, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CNAffiliated Zhongshan Hospital of Dalian University · CNSecond Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Monitoring the response after treatment of liver cancer and timely adjusting the treatment strategy are crucial to improve the survival rate of liver cancer. At present, the clinical monitoring of liver cancer after treatment is mainly based on serum markers and imaging. Morphological evaluation has limitations, such as the inability to measure small tumors and the poor repeatability of measurement, which is not applicable to cancer evaluation after immunotherapy or targeted treatment. The determination of serum markers is greatly affected by the environment and cannot accurately evaluate the prognosis. With the development of single cell sequencing technology, a large number of immune cell-specific genes have been identified. Immune cells and microenvironment play an important role in the process of prognosis. We speculate that the expression changes of immune cell-specific genes can indicate the process of prognosis. Method: Therefore, this paper first screened out the immune cell-specific genes related to liver cancer, and then built a deep learning model based on the expression of these genes to predict metastasis and the survival time of liver cancer patients. We verified and compared the model on the data set of 372 patients with liver cancer. Result: The experiments found that our model is significantly superior to other methods, and can accurately identify whether liver cancer patients have metastasis and predict the survival time of liver cancer patients according to the expression of immune cell-specific genes. Discussion: We found these immune cell-specific genes participant multiple cancer-related pathways. We fully explored the function of these genes, which would support the development of immunotherapy for liver cancer.

Indexed as

Liver NeoplasmsBiomarkersHumansImmunotherapyPrognosisTumor MicroenvironmentBiomarkerscell markerdeep learningimmune cellliver cancerprognosis

Identifiers

PMID37180166
PMCPMC10174299
OpenAlexW4367291484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.